Drug Discovery Laboratory Articles & Analysis
20 news found
New role will lead technology development as the Company continues to scale team and global business operations. The appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software Optibrium a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian ...
Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based appointments with proven AI and life science expertise will support the next phase of commercial growth for Optibrium’s computational drug discovery technologies. Optibrium, a leading developer of software and artificial ...
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ...
Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (PCC) targeting methionine adenosyltransferase 2A (MAT2A) from AI-designed molecules for the treatment of methylthioadenosine phosphorylase (MTAP)-deleted cancers. The PCC is part of Insilico's growing ...
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part ...
TEL AVIV, Israel and SEOUL, South Korea, April 12, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced today the signing of a commercial partnership with Helixrus, a leading Korean company focused on biological big data and multi-omics. The partnership will see Helixrus represent CytoReason's unique AI ...
London, 3 February 2022, BenevolentAI, a leading clinical-stage AI-drug discovery company, today announced details of an AI research collaboration with the Helix Group, a Stanford University-based research lab led by Professor Russ Altman. The partnership aims to discover more effective methods to extract knowledge from biological and clinical information and ultimately extend the potential of ...
Two novel targets identified through the existing collaboration have already been added to AstraZeneca’s portfolio London, 13 January 2021, BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership. The three-year expansion includes ...
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT. About BenevolentAI BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the ...
Novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca Announcement represents the second collaboration milestone following the addition of a novel chronic kidney disease target to AstraZeneca’s portfolio in Q1 2021 London, 15 December 2021: BenevolentAI, a leading ...
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology ...
Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). ...
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the appointment of Jeffrey Brown, Ph.D., Vice President, Preclinical Research. Jeffrey will be responsible for advancing programs into IND-enabling studies, overseeing the discipline of experimental biology, and working with the leadership team on scientific and business strategies. Fueled by their AI ...
Ataxia UK is the leading charity in the United Kingdom for people affected by ataxia - an umbrella term for a group of neurological disorders that target the nervous system and affect balance, coordination and speech. FARA (Friedreich’s Ataxia Research Alliance) is a non-profit organisation in the US, dedicated to supporting research into treatments and cures for Friedreich’s ataxia, ...
Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies for 2021. Atomwise was recognized for its unmatched AI platform, AtomNet®?, as well as its growing pipeline and portfolio of partnerships and joint ventures tackling some of the most ...
Biotech firm PercayAI and Saint Louis University (SLU) announced a partnership today to provide SLU researchers with access to PercayAI’s augmented intelligence (AI) drug discovery platform. One of the primary components of the PercayAI platform is CompBio™, software co-developed with the Genome Technology Access Center at the McDonnell Genome Institute (GTAC@MGI) at Washington ...
ByPercayAI
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech ...
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics’ artificial intelligence drug discovery platform (The AI Workbench) to identify oligonucleotide drug candidates in four rare disease indications with high unmet need. Deep Genomics will receive an undisclosed upfront ...
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today $2.3M in grant ...
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and ...